Tasly Pharmaceuticals, Inc. (TPI) is a U.S.-based biopharmaceutical company focused on advancing botanical drug development through scientific research, clinical evaluation, and global collaboration. TPI works with strategic partners across the pharmaceutical, biotechnology, and healthcare sectors to support the development of innovative therapeutic solutions for patients in the United States and international markets.
TPI’s development approach is grounded in the rigorous scientific evaluation of botanical medicines, integrating well-characterized Traditional Chinese Medicine (TCM) principles with modern drug development standards, regulatory science, and clinical research methodologies. This integrated model supports the advancement of complex, multi-component therapeutic products within established regulatory frameworks.
Botanical Drug Development and Scientific Approach
TPI focuses on the development of evidence-based botanical drug products aligned with U.S. Food and Drug Administration (FDA) regulatory expectations. The company emphasizes product quality, consistency, and data-driven development throughout the product lifecycle.
By applying advanced analytical technologies, systems biology, pharmacological research, and real-world data integration, TPI supports the translation of traditional botanical knowledge into scientifically evaluated therapeutic candidates. This approach enables the development of botanical drugs within structured clinical and regulatory pathways.
Clinical Development and Regulatory Experience
TPI has established experience in conducting FDA-regulated clinical trials and advancing botanical drug candidates through the regulatory process. The company supports clinical trial design, execution, and oversight in accordance with Good Clinical Practice (GCP) standards and applicable regulatory requirements.
A representative program includes T89 (Dantonic®), a botanical drug candidate that has completed a Phase III global clinical trial under FDA oversight. Clinical studies have generated data evaluating endpoints related to cardiovascular function, including microcirculation, energy metabolism, and blood viscosity-related parameters.
TPI continues to engage with regulatory agencies to support ongoing development programs, future submissions, and global registration strategies.
Integrated Development Capabilities
TPI offers a comprehensive development platform that supports partners across multiple stages of product development, including:
- Botanical drug research and development
- FDA-regulated clinical trial execution and management
- Contract research organization (CRO) services
- Regulatory strategy and global development planning
- Data management, quality systems, and compliance oversight
The company operates in alignment with current Good Manufacturing Practices (cGMP), Good Clinical Practices (GCP), and FDA botanical drug development guidance, supported by established systems for data integrity and quality assurance.
Strategic Collaboration and Global Engagement
TPI collaborates with industry partners, research institutions, and healthcare organizations to advance botanical therapeutics through cross-border development initiatives. The company’s experience in global clinical development and regulatory engagement supports collaboration in areas such as co-development, licensing, and clinical research partnerships.
Through participation in international programs, regulatory dialogue, and industry forums, TPI contributes to the advancement of botanical drug development within the global pharmaceutical landscape.
Why Partner with TPI
TPI provides a collaboration model supported by:
- Regulatory expertise: Experience with FDA botanical drug development pathways and global regulatory frameworks
- Scientific foundation: Integration of pharmacology, systems biology, and clinical research methodologies
- Quality systems: Alignment with cGMP, GCP, and data integrity standards
- Development platform: Application of analytical technologies and real-world data
- Global capabilities: Cross-border collaboration and international development experience
Market Context: Botanical Therapeutics
The global healthcare environment continues to evolve, with increasing focus on:
- Well-tolerated therapeutic approaches for chronic and complex conditions
- Multi-target treatment strategies
- Integration of evidence-based natural products into healthcare systems
- Scientific validation of traditional medicine approaches
Regulatory agencies, including the FDA, have established clearer pathways for botanical drug development, supporting the advancement of scientifically evaluated botanical products within regulated frameworks.
TPI’s development approach aligns with these trends, supporting the continued evolution of botanical therapeutics in modern medicine.
About Tasly Pharmaceuticals, Inc.
Tasly Pharmaceuticals, Inc. is dedicated to advancing human health through safe and effective therapeutic solutions. The company focuses on the modernization of botanical medicines through scientific evaluation, including clinical and pharmacological research.
Founded in 2006 and based in Rockville, Maryland, TPI advances innovation in botanical therapeutics through scientific research, global collaboration, and integrated development initiatives.